Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849210 | 0.84 | MYC (0.45) | HTR6MYCDRD2 | |
| Water SCHEMBL5996484 | 0.83 | MYC (0.44) | HTR6MYCDRD2 | |
| SCHEMBL6849293 | 0.83 | HTR6 (0.43) | HTR6MYCADRB1DRD2NOTUM | |
| SCHEMBL6849062 | 0.81 | RPS6KB1 (0.47) | HTR6MYCNOTUMRPS6KB1 | |
| SCHEMBL6848056 | 0.80 | LATS1 (0.40) | HTR6MYCADRB1DRD2NOTUM | |
| SCHEMBL6847420 | 0.80 | HDAC1 (0.41) | HTR6MYCADRB1DRD2 | |
| SCHEMBL2851145 | 0.78 | ADRB1 (0.41) | HTR6MYCADRB1DRD2CA2 | |
| SCHEMBL6847591 | 0.78 | HTR6 (0.39) | HTR6MYCNOTUM | |
| SCHEMBL8632814 | 0.77 | HTR6 (0.67) | HTR6MYCADRB1DRD2 | |
| Water SCHEMBL6904877 | 0.76 | HTR6 (0.65) | HTR6MYCADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100486574-C | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2009-05-13 | — | — | CN | claimed |
| CN-1946396-A | Medicine for prevention and/or treatment of ischemic circulatory disease | MITSUBISHI PHARMA CORP (JP) | 2007-04-11 | — | — | CN | claimed |
| CN-1638773-A | Pharmaceutical preparation containing aminobenzenesulfonic acid derivative as active ingredient | MITSUBISHI PHARMA CORP (JP) | 2005-07-13 | — | — | CN | claimed |
| CN-1533292-A | Medicament inhititing sodium/calcium exchange system | 三菱制药株式会社 | 2004-09-29 | — | — | CN | claimed |
| CN-1496261-A | Remedies and/or preventives for diabetic ischemic heart diseases | 三菱制药株式会社 | 2004-05-12 | — | — | CN | claimed |
| EP-1374868-A1 | REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES | Mitsubishi Pharma Corporation (JP) | 2004-01-02 | — | — | EP | claimed |
| CN-1434724-A | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-08-06 | — | — | CN | claimed |
| CN-100502861-C | Medicament inhibiting sodium/calcium exchange system | MITSUBISHI PHARMA CORP (JP) | 2009-06-24 | — | — | CN | disclosed |
| CN-100486574-C | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2009-05-13 | — | — | CN | disclosed |
| CN-1946396-A | Medicine for prevention and/or treatment of ischemic circulatory disease | MITSUBISHI PHARMA CORP (JP) | 2007-04-11 | — | — | CN | disclosed |
| CN-1638773-A | Pharmaceutical preparation containing aminobenzenesulfonic acid derivative as active ingredient | MITSUBISHI PHARMA CORP (JP) | 2005-07-13 | — | — | CN | disclosed |
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-09 | — | — | US | disclosed |
| CN-1533292-A | Medicament inhititing sodium/calcium exchange system | 三菱制药株式会社 | 2004-09-29 | — | — | CN | disclosed |
| CN-1496261-A | Remedies and/or preventives for diabetic ischemic heart diseases | 三菱制药株式会社 | 2004-05-12 | — | — | CN | disclosed |
| EP-1374868-A1 | REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES | Mitsubishi Pharma Corporation (JP) | 2004-01-02 | — | — | EP | disclosed |
| CN-1434724-A | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | SLC5A1, FABP3, IAPP | HTR6 1339/4885MYC 3787/4885ADRB1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.